CGRP & Migraine Research
Explore migraine research on CGRP biology, CGRP-targeted treatments, efficacy, safety and emerging therapeutics.
-
Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study.
Authors: Kamogawa M, Higurashi M, Oshima A, Higurashi N, Ikegaya N Observational study
CGRP monoclonal antibodies (mAb) could help adolescents with migraines. This study focused on adolescents aged 15-17 years who received CGRP mAb therapy for migraine. It evaluated early functional outcomes in daily…
-
Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.
Authors: Seo D, Kim M, Lee MJ, Chu MK, Cho SJ Observational study
Fremanezumab is being evaluated for its safety and effectiveness in South Korea. This study focuses on adults with migraines using fremanezumab for the first time. It is a 6-year, non-interventional study across 60…
-
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).
Authors: Gago-Veiga AB, Lopez-Rodriguez AB, Sanchez Jimenez M, Iglesias Rubio A, Montes N Observational study
Rimegepant is a CGRP receptor antagonist for treating episodic migraines. This study examined rimegepant's effectiveness in patients with previous treatment failures. It was conducted across nine headache units in…
-
Trigeminovascular calcitonin gene-related peptide release and peripheral vascular responses in a mouse model of accelerated aging: Implications for migraine.
Authors: Al-Hassany L, Rubio-Beltrán E, Labastida-Ramirez A, Garrelds IM, Danser AHJ Laboratory / animal study
Understanding age-related changes in migraine is crucial as life expectancy increases. Both aging and migraine are significant cardiovascular risk factors. Researchers studied how calcitonin gene-related peptide…
-
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.
Authors: Bond DS, Smith JH, Sinclair A, Goadsby PJ, Ailani J Clinical trial
This study examined weight loss with atogepant 60 mg daily for migraine treatment. Participants had chronic or episodic migraine and had previously failed several medications. Obesity increases migraine risk…
-
CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?
Authors: Tarnutzer AA, Castro Abarca P, Kaski D Clinical trial
CGRP-targeted therapies have shown promise in reducing migraine symptoms for many patients. However, evidence for their effectiveness in vestibular migraine is limited and preliminary. Current literature on…
-
Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience.
Authors: Gomaa MA, Taha NA, Helmy SM, Farag SM, Moustafa RR Observational study
This study evaluated the real-world use of anti-CGRP therapies in Egypt. Researchers focused on effectiveness, tolerability, barriers to access, and treatment adherence. Eighty migraine patients participated…
-
Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program.
Authors: Gül S, Ong B, Trudeau S, Thompson N, Yuan H Observational study
In a study comparing treatments for migraine, researchers evaluated calcitonin gene-related peptide monoclonal antibodies, or CGRP mAbs, and onabotulinumtoxinA. They aimed to determine if CGRP mAbs were non-inferior…
-
[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].
Authors: Ishikawa T, Morota S, Shi B, Li Y, Iijima M Review
Migraine is a common neurological disorder that causes significant burden on individuals. Current treatments face challenges like contraindications and delayed effectiveness. Rimegepant is a new oral medication…
-
Galcanezumab in chronic migraine
Authors: Detke et al. Clinical trial
This study evaluated galcanezumab's effectiveness for preventing chronic migraines. Galcanezumab is a humanized monoclonal antibody targeting calcitonin gene-related peptide. It was tested in a phase 3, randomized…
MigraineMind Top 100 · #55 -
Evaluation of Galcanezumab for the Prevention of Episodic Migraine
Authors: Stauffer et al. Clinical trial
Migraine is a debilitating condition marked by severe headache attacks. Current treatments often reduce migraine frequency but can cause adverse effects. This study assessed galcanezumab's efficacy compared to…
MigraineMind Top 100 · #57 -
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Authors: Edvinsson et al. Review
Migraine treatment is entering a transformative era focused on CGRP-targeted therapies. These drugs target calcitonin gene-related peptide or its receptor, enhancing migraine management. Approval for several of these…
MigraineMind Top 100 · #12 -
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Authors: Dodick et al. Clinical trial
Erenumab is a monoclonal antibody that targets the calcitonin gene-related peptide receptor. This study evaluated erenumab's effectiveness for preventing episodic migraines. Five hundred seventy-seven adults…
MigraineMind Top 100 · #52 -
A Controlled Trial of Erenumab for Episodic Migraine
Authors: Goadsby et al. Clinical trial
In this study, researchers evaluated erenumab for preventing episodic migraine. Erenumab is a monoclonal antibody that inhibits a specific receptor. Patients received a monthly injection of either 70 mg, 140 mg, or…
MigraineMind Top 100 · #17 -
Fremanezumab for the Preventive Treatment of Chronic Migraine
Authors: Silberstein et al. Clinical trial
Fremanezumab is a monoclonal antibody aimed at preventing chronic migraines. This study compared its effectiveness to placebo in a phase 3 trial. Patients with chronic migraines received one of three treatments. They…
MigraineMind Top 100 · #26 -
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Authors: Tepper et al. Clinical trial
The study explored erenumab's safety and efficacy in chronic migraine patients. Researchers conducted a phase 2, randomized, double-blind trial across 69 centers in North America and Europe. Participants were adults…
MigraineMind Top 100 · #32 -
Cgrp May Play A Causative Role in Migraine
Authors: Lassen et al. Clinical trial
Calcitonin gene-related peptide, or CGRP, is linked to migraine attacks. This study investigated if CGRP causes headaches or is a result of migraines. Twelve patients with migraine without aura participated in a…
MigraineMind Top 100 · #33